Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study

References

• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Le Claire M. The expenditures for academic inpatient care of inflammatory bowel disease patients are almost double compared with average academic gastroenterology and hepatology cases and not fully recovered by diagnosis-related group (DRG) proceeds. PLoS One 2016;11(1):e0147364.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2):257.
   PubMed Web of Science ®Google Scholar
• Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4(4):355–366.
   PubMed Web of Science ®Google Scholar
• Scott FI, Johnson FR, Bewtra M, et al. Improved quality of life with anti-TNF therapy compared with continued corticosteroid utilization in Crohn's disease. Inflamm Bowel Dis. 2019;25(5):925–936.
   PubMed Web of Science ®Google Scholar
• Ma C, Moran GW, Benchimol EI, et al. Surgical rates for Crohn's disease are decreasing: a Population-based time trend analysis and validation study. Am J Gastroenterol. 2017;112(12):1840–1848.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–623.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353.
   PubMed Web of Science ®Google Scholar
• Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease-role of vedolizumab. Drug Des Devel Ther. 2015;9:147–154.
   PubMed Web of Science ®Google Scholar
• Cherry LN, Yunker NS, Lambert ER, et al. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease. Ther Adv Chronic Dis. 2015;6(5):224–233.
   PubMed Web of Science ®Google Scholar
• Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33–52.
   PubMedGoogle Scholar
• Lobaton T, Vermeire G, Van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579–594.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229–239.e5.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Loftus EV, Colombel J-F, et al. Long-term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis 2017;11(4):412–424.
   PubMed Web of Science ®Google Scholar
• De Vos M, Dhooghe B, Vermeire S, et al., Belgian Inflammatory Bowel Disease Research and Development (BIRD). Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterol J. 2018;6(3):439–445.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naive to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97–106.
   PubMed Web of Science ®Google Scholar
• Berends S, Löwenberg M, Baert F, et al. DOP046 Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial. ECCO. 2018;12(Supp 1):S063–S063.
   Google Scholar
• Danese S, Sandborn WJ, Colombel J-F, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease. Gastroenterology 2019;157(4):1007–1018.e7.
   PubMed Web of Science ®Google Scholar
• Samaan MA, Pavlidis P, Johnston E, et al. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2017;8(3):196–202.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the Cross Pennine study. Dig Liver Dis. 2018;50(12):1299–1304.
   PubMedGoogle Scholar
• Plevris N, Chuah CS, Allen RM, et al. Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish Vedolizumab Cohort. J Crohns Colitis 2019;13(9):1111–1120.
   PubMed Web of Science ®Google Scholar
• European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. [cited 2020 Jul 3]. Available from: www.encepp.eu.
   Google Scholar
• Public Policy Committee, International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2016;25:2–10. DOI:10.1002/pds.3891
   Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al., European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017;11(6):649–670.
   PubMed Web of Science ®Google Scholar
• Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis 2017;11(1):3–25.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1(8167):514.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660–1666.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al., OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–321.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Bokemeyer B, Drabik A, et al., Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice-a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43(10):1090–1102.
   PubMed Web of Science ®Google Scholar
• Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879–2885.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Ron Y, Avni-Biron I, et al. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the Israeli real-world experience. Inflamm Bowel Dis. 2017;23(3):404–408.
   PubMed Web of Science ®Google Scholar
• Engel T, Ungar B, Yung DE, et al. Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis. J Crohns Colitis 2018;12(2):245–257.
   PubMed Web of Science ®Google Scholar
• Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy: NICE technology appraisal guidance [TA352]. 2015. [cited 2020 Jul 3]. Available from: http://www.nice.org.uk/guidance/ta352.
   Google Scholar
• Vedolizumab for treating moderately to severely active ulcerative colitis: NICE technology appraisal guidance [TA342]. 2015. [cited 2020 Jul 3]. Available from: http://www.nice.org.uk/guidance/ta342.
   Google Scholar
• Cummings F, Gaya DR, Levison S, et al. A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: the REVIVE study. Medicine (Baltimore), 2019;98(9):e14681.
   PubMed Web of Science ®Google Scholar
• Ylisaukko-Oja T, Aaltonen J, Nuutinen H, et al. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scand J Gastroenterol. 2018;53(2):158–167.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44(11–12):1199–1212.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Peyrin-Biroulet L, Loftus EV, et al. OP34 VARSITY: a double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. J Crohns Colitis 2019;13(Suppl 1):S612–S613.
   Google Scholar
• Shim HH, Chan PW, Chuah SW, et al. A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2018;2(5):223–234.
   PubMed Web of Science ®Google Scholar
• Amiot A, Grimaud J-C, Peyrin-Biroulet L, et al., Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593–1601.e2.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium. Am J Gastroenterol. 2016;111(8):1147–1155.
   PubMed Web of Science ®Google Scholar
• Kotze PG, Ma C, Almutairdi A, et al. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(6):626–637.
   PubMed Web of Science ®Google Scholar
• Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3–15.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146(2):392–400.e3.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Loftus EV, Siegel CA, et al. Sa1270 efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with Crohn’s disease from GEMINI 2. Gastroenterology 2015;148(4):S-277.
   Web of Science ®Google Scholar
• Allegretti JR, Barnes EL, Stevens B, et al. Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab. Dig Dis Sci. 2017;62(6):1590–1596.
   PubMed Web of Science ®Google Scholar